



ESM 9. Fig. 1b. Forest plot of hazard ratios of rivaroxaban versus VKAs for the major efficacy endpoint (stroke, stroke/SE, Stroke/TIA, etc.). If a specific subgroup was analyzed this is indicated after the indicator 'R' in the right column, a number after R refers to the dose in mg once per day. The meta-analytical DerSimonian-Laird random effect estimate is indicated as a diamond in the last line and by the dashed line. Overall heterogeneity test with I-squared and p-value is shown in the last line on the left side.